Fresh Equities
Offers
Learn
AMPLIA THERAPEUTICS LIMITED

INVESTOR PRESENTATION - AMPLIA THERAPEUTICS LIMITED

ASX:ATX

AMPLIA THERAPEUTICS LIMITED

Health Care

Amplia Therapeutics Limited (ASX:ATX) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Amplia has two core patent families over its FAK assets. Their ideology is that FAK is an increasingly important target in the field of cancer immunology and that FAK inhibition has the potential to sensitize treatment-resistant cancers to the existing chemotherapeutics. With FAK in mind, Amplia has a particular development focus in pancreatic and ovarian cancer.

Read more

Market Cap

15.95m

Price at Close

$0.15

4w avg. Volume

259.07k

4w avg. Turnover

$37.48k

Announcements
announcementt+2 movementdate
  • Change of Director's Interest Notice - Dr. Warwick Tong

    Shareholder Details

  • -

    18 Sep 2020

-

18 Sep 2020
  • Change of Director's Interest Notice - Dr. Robert Peach

    Shareholder Details

  • -

    18 Sep 2020

-

18 Sep 2020
  • Change of Director's Interest Notice - Dr. C. Burns

    Shareholder Details

  • -

    18 Sep 2020

-

18 Sep 2020
  • Section 708A Cleansing Notice - Allotment of Shares

    Issued Capital

  • -

    18 Sep 2020

-

18 Sep 2020
  • Appendix 2A - Application for Quotation of Shares

    Issued Capital

  • -

    18 Sep 2020

-

18 Sep 2020
  • Results of Annual General Meeting

    Notice Of Meeting

  • -

    18 Sep 2020

-

18 Sep 2020
  • CEO Presentation to AGM

    Chairman's Address

  • -

    17 Sep 2020

-

17 Sep 2020
  • Amplia Receives Ethics Clearance fo Conduct Phase 1 Trial

    Progress Report · Market sensitive

  • -3.57%

    07 Sep 2020

-3.57%

07 Sep 2020
  • Appendix 3G - Notification of Issue of Securities - Options

    Issued Capital

  • 0.00%

    02 Sep 2020

0.00%

02 Sep 2020
  • Amplia Appoints Dr Mark Devlin as Chief Scientific Officer

    Company Administration

  • -7.14%

    30 Aug 2020

-7.14%

30 Aug 2020
Market Data

Current Price

$0.15

52WK HIGH

$0.24

52WK LOW

$0.045

1YR RETURN

+87.50%

1YR RETURN VS. SECTOR

+57.32%

90 DAY RETURN

+25.00%

ASX RANK

1,495

/2,019

SECTOR RANK

38

/47

SHARES OUTSTANDING

106.34m
ASX:ATX

AMPLIA THERAPEUTICS LIMITED

Health Care

Amplia Therapeutics Limited (ASX:ATX) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Amplia has two core patent families over its FAK assets. Their ideology is that FAK is an increasingly important target in the field of cancer immunology and that FAK inhibition has the potential to sensitize treatment-resistant cancers to the existing chemotherapeutics. With FAK in mind, Amplia has a particular development focus in pancreatic and ovarian cancer.

Read more

Market Cap

15.95m

Price at Close

$0.15

4w avg. Volume

259.07k

4w avg. Turnover

$37.48k

ASX:ATX is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Support

Ask Fresh

Archive
Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.